Get to know our clinical trials
"Phase I/II, open-label clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ODM-216 in participants with advanced solid tumors."
THIS IS THE FIRST TIME ODM-216 IS BEING TESTED IN HUMANS. ODM-216 IS A TYPE OF IMMUNOTHERAPY. IT WORKS BY HELPING THE IMMUNE SYSTEM BETTER RECOGNIZE AND RESPOND TO CANCER. THE PRIMARY OBJECTIVE OF THIS STUDY IS TO DETERMINE THE SAFETY AND TOLERABILITY OF ODM-216 AND ESTABLISH THE OPTIMAL DOSE.
Technical Summary
- FIRST-IN-HUMAN, PHASE I/II, OPEN-LABEL TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ODM-216 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2026-525864-17-00
- Protocol number: 3138001
- Promoter: Orion Corporation, Orion Pharma
- Molecule/Drug: ODM-216
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.